chartexchange

Pharming Reports Positive Phase II Data For Leniolisib In Rare Genetic Immune Disorders

RTTNews | Oct 14, 2026 3:02 AM EDT


(RTTNews) - On Wednesday, Pharming Group N.V. (PHAR) announced positive topline results from a Phase II study evaluating Leniolisib in patients with genetically identifiable primary immunodeficiencies (PIDs) associated with immune dysregulation linked to altered PI3Kdelta signa

Read original article